These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 8044994)

  • 21. [Acid-base equilibrium of peritoneal dialysis (CAPD) patients utilizing acetate, lactate, bicarbonate].
    Quellhorst E
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1995 Oct; 30 Suppl 1():S69-72. PubMed ID: 8589123
    [No Abstract]   [Full Text] [Related]  

  • 22. Effects of ascorbic acid and pyridoxine supplementation on oxalate metabolism in peritoneal dialysis patients.
    Shah GM; Ross EA; Sabo A; Pichon M; Reynolds RD; Bhagavan H
    Am J Kidney Dis; 1992 Jul; 20(1):42-9. PubMed ID: 1621677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis.
    Montenegro J; Saracho R; Gallardo I; Martínez I; Muñoz R; Quintanilla N
    Nephrol Dial Transplant; 2007 Jun; 22(6):1703-8. PubMed ID: 17405794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The determination of oxalate in haemodialysate and plasma: a means to detect and study 'hyperoxaluria' in haemodialysed patients.
    Wolthers BG; Meijer S; Tepper T; Hayer M; Elzinga H
    Clin Sci (Lond); 1986 Jul; 71(1):41-7. PubMed ID: 3709074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal replacement therapy and secondary hyperoxalemia in chronic renal failure.
    Mydlík M; Derzsiová K
    Kidney Int Suppl; 2001 Feb; 78():S304-7. PubMed ID: 11169031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxalate quantification in hemodialysate to assess dialysis adequacy for primary hyperoxaluria.
    Tang X; Voskoboev NV; Wannarka SL; Olson JB; Milliner DS; Lieske JC
    Am J Nephrol; 2014; 39(5):376-82. PubMed ID: 24776840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Acetate dialysate: responsible for decrease in ultrafiltration in continuous ambulatory peritoneal dialysis].
    Faller B; Marichal JF
    Nephrologie; 1984; 5(2):71-6. PubMed ID: 6483075
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary hyperoxaluria in an adult with renal failure, livedo reticularis, retinopathy, and peripheral neuropathy.
    Farreli J; Shoemaker JD; Otti T; Jordan W; Schoch L; Neu LT; Bastani B
    Am J Kidney Dis; 1997 Jun; 29(6):947-52. PubMed ID: 9186083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of oxalate balance in patients on chronic peritoneal dialysis.
    Marangella M; Bagnis C; Bruno M; Petrarulo M; Gabella P; Linari F
    Am J Kidney Dis; 1993 Apr; 21(4):419-26. PubMed ID: 8465823
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of vitamin B6 supplementation on plasma oxalate and oxalate removal rate in hemodialysis patients.
    Costello JF; Sadovnic MC; Smith M; Stolarski C
    J Am Soc Nephrol; 1992 Oct; 3(4):1018-24. PubMed ID: 1450364
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a new bicarbonate/lactate-buffered neutral peritoneal dialysis fluid for peritoneal failure in patients undergoing peritoneal dialysis.
    Hoshino T; Ishii H; Kitano T; Shindo M; Miyazawa H; Yamada H; Ito K; Ueda Y; Kaku Y; Hirai K; Mori H; Ookawara S; Tabei K; Morishita Y
    Discov Med; 2016 Feb; 21(114):81-8. PubMed ID: 27011043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients.
    Feriani M; Passlick-Deetjen J; Jaeckle-Meyer I; La Greca G;
    Nephrol Dial Transplant; 2004 Jan; 19(1):195-202. PubMed ID: 14671057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of acetate and bicarbonate on the tolerance for hemodialysis therapy in chronic kidney failure].
    Shostka GD; T'iagi S; Kulikova AI; Spiridonov VN; Kostkina MI; Vitenberg AG
    Urol Nefrol (Mosk); 1990; (6):39-44. PubMed ID: 2089765
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma oxalate following kidney transplantation in patients without primary hyperoxaluria.
    Elgstoen KB; Johnsen LF; Woldseth B; Morkrid L; Hartmann A
    Nephrol Dial Transplant; 2010 Jul; 25(7):2341-5. PubMed ID: 20167571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study.
    Fusshoeller A; Plail M; Grabensee B; Plum J
    Nephrol Dial Transplant; 2004 Aug; 19(8):2101-6. PubMed ID: 15213322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clearance and removal of oxalate in children on intensified dialysis for primary hyperoxaluria type 1.
    Illies F; Bonzel KE; Wingen AM; Latta K; Hoyer PF
    Kidney Int; 2006 Nov; 70(9):1642-8. PubMed ID: 16955107
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxalate, silicon and vanadium in acquired cystic kidney disease.
    Marco-Franco JE; Torres VE; Nixon DE; Wilson DM; James EM; Bergstralh EJ; McCarthy JT
    Clin Nephrol; 1991 Feb; 35(2):52-8. PubMed ID: 2019015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary oxalate and glycolate excretion and plasma oxalate concentration.
    Barratt TM; Kasidas GP; Murdoch I; Rose GA
    Arch Dis Child; 1991 Apr; 66(4):501-3. PubMed ID: 2031609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary hyperoxalemia in chronic renal failure.
    Balcke P; Schmidt P; Zazgornik J; Kopsa H; Deutsch E
    Int J Artif Organs; 1982 May; 5(3):141-3. PubMed ID: 7107047
    [No Abstract]   [Full Text] [Related]  

  • 40. Acetate metabolism, organic acid production, and the independent effects of bicarbonate and acetate as alkalinizing agents in dialysis bath solutions.
    Gennari FJ; Sargent JA
    Semin Dial; 2019 May; 32(3):274-275. PubMed ID: 31006902
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.